Headquartered in Woburn, MA Fiscal year ends March NASDAQ: REPL replimune.com
Replimune Group, Inc. is a commercial-stage biotechnology company focused on developing novel oncolytic immunotherapies for cancer treatment. The company's proprietary RPx platform is based on a potent HSV-1 (herpes simplex virus type 1) backbone engineered to maximize immunogenic cell death and induce systemic anti-tumor immune responses. Replimune's lead product, TUDRIQEV (vusolimogene oderparepvec-wtpg), received FDA accelerated approval in August 2026 for use in combination with nivolumab to treat adults with unresectable advanced cutaneous melanoma who progressed on PD-1 antibody-based therapy. The company's pipeline also includes RP2, which expresses an anti-CTLA-4 antibody-like molecule alongside GALV-GP R- and GM-CSF, currently in a registration-directed Phase 2/3 trial (REVEAL) for metastatic uveal melanoma. Replimune's therapeutic approach involves direct injection of engineered viruses into tumors to kill cancer cells, release tumor antigens, and stimulate a broader immune response that can target distant metastases. The company trades on Nasdaq under the ticker REPL. Updated
Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the market's biggest names with fresh upgrades, downgrades, and new coverage that could…
Replimune Group, Inc. is a commercial-stage biotechnology company focused on developing novel oncolytic immunotherapies for cancer treatment.
The Wall Street consensus 12-month price target for REPL is $19.50.
